Abivertinib

DRUG2 trials

Sponsors

Sorrento Therapeutics, Inc.

Conditions

Covid-19Prostate CancerProstate Cancer Metastatic

Phase 2

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

CompletedNCT04440007

Sorrento Therapeutics, Inc.Covid-19

Start: 2020-10-09End: 2021-08-23Updated: 2023-01-18

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

SuspendedNCT05361915

Sorrento Therapeutics, Inc.Prostate Cancer, Prostate Cancer Metastatic

Start: 2025-09-30End: 2028-01-31Target: 100Updated: 2024-03-18

Related Papers

The Maverick trial: A phase 2 study of abivertinib in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2023-06-012 citations

BMX inhibition and <i>HSD3B1</i>-driven resistance in prostate cancer in the Maverick trial.

Journal of Clinical Oncology2023-02-20